Hughes, Dallas
- Novobiotic Pharmaceuticals, LLC (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #3,347
- R01 Holder
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2014 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$2.1M
Full award amounts, FY2023
Award Records
2
Records listing this PI
Award-Linked Rank
#3,347
By linked amount among FY2023 PIs
Earliest Year Loaded
2014
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Hughes, Dallas as a PI. Multi-PI records show the full award amount for context.
- 5R01AI159444-03R01Contact PIDeveloping Teixobactin for Respiratory Infections$1.1Maward amount
- $996.3Kaward amount
Award organization
Organizations that administered FY2023 awards listing Hughes, Dallas as a PI.
FY2023 award administered by Novobiotic Pharmaceuticals, LLC (MA).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2014First NIH AwardNovobiotic Pharmaceuticals, LLC
- 2015$500K Cumulative Funding
- 2015$1M Cumulative Funding
- 2015Entered Top 50% NationallyRanked #6523
- 2016$2M Cumulative Funding
- 2016Entered Top 25% NationallyRanked #4123
- 2017R01 Grant Holder
- 2019$5M Cumulative Funding
- 2022$10M Cumulative Funding
- 2022Entered Top 10% NationallyRanked #1586